VXF Overview

Stock Split Announcement: Atossa Therapeutics has combined its 15 shares of common stock into one new share following a reverse stock split approved by its Board of Directors, effective February 2, 2026.

FDA Orphan Drug Designation: The FDA granted Orphan Drug Designation to Atossa's drug, Z-endoxifen, for the treatment of Duchenne muscular dystrophy, which is a severe genetic disorder primarily affecting boys.

Stock Performance: Following the stock split, Atossa's shares fell by 32% on the first day of trading, reflecting ongoing concerns among investors about potential dilution and the company's overall performance.

Financial Position: As of the end of September, Atossa reported cash and cash equivalents totaling $51.8 million, despite experiencing a 54% decline in stock value over the past year.

ARK Invest's Stake in CoreWeave: Cathie Wood's ARK Invest has significantly increased its investment in CoreWeave, purchasing over 800,000 shares worth approximately $59.5 million despite a recent decline in the stock price due to Nvidia GPU reliance concerns.

Long-Term Confidence in AI Growth: The continued purchases reflect ARK's confidence in CoreWeave's long-term growth potential, driven by increasing demand for AI computing power and new contracts with major tech firms, even as the stock has dropped nearly 48% in the past month.

Ownership Breakdown: Public companies and individual investors hold 76.58% of CoreWeave, with CW Opportunity LLC being the largest shareholder at 7.77%, followed by Philippe Laffont at 4.68%.

Analyst Ratings and Price Target: Analysts have a Moderate Buy consensus on CoreWeave, with 12 Buys, 11 Holds, and one Sell, and an average price target of $148.32 per share, indicating a potential upside of about 108%.

CoreWeave Q3 Results Announcement: CoreWeave is set to announce its third-quarter results on November 10, with expectations of a loss per share of $0.40 on revenue of $1.29 billion, despite a strong year-over-year revenue growth of 207% in Q2 2025.

Stock Performance and Analyst Sentiment: Despite a recent pullback in shares and concerns over high debt and customer concentration, CoreWeave's stock is up 168% from its IPO price, with analysts maintaining a Moderate Buy consensus rating and a price target indicating 46% upside potential.

Partnership with Vast Data: Ahead of the Q3 results, CoreWeave announced a $1.17 billion commercial agreement with AI startup Vast Data, reflecting the growing demand for AI infrastructure.

Ownership Structure: Public companies and individual investors hold 76.58% of CoreWeave, with CW Opportunity LLC being the largest shareholder at 7.77%, while various ETFs and mutual funds also hold minor stakes in the company.

Vanguard Extended Market ETF Overview: The Vanguard Extended Market ETF (VXF) is a Mid-Cap Value ETF with significant exposure to the Technology sector, particularly in Software & Programming.

Investment Factor Analysis: The report provides a detailed analysis of VXF's exposure to key investing factors such as value, quality, momentum, and low volatility, scoring from 1 to 99.

VXF Performance Overview: VXF's 52-week low is $146.68 and its high is $207.77, with the last trade recorded at $185.98.

Author's Perspective: The opinions expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.

VXF Stock Performance: VXF's stock has a 52-week low of $159.39 and a high of $207.77, with the last trade recorded at $182.61.

Market Analysis Note: The article includes a reference to other ETFs that have recently fallen below their 200-day moving average, indicating potential market trends.